312 related articles for article (PubMed ID: 1530916)
21. The immune response and the eye: a role for TNF alpha in anterior chamber-associated immune deviation.
Ferguson TA; Herndon JM; Dube P
Invest Ophthalmol Vis Sci; 1994 Apr; 35(5):2643-51. PubMed ID: 8163352
[TBL] [Abstract][Full Text] [Related]
22. Anterior chamber-associated immune deviation induced by soluble antigens.
Mizuno K; Clark AF; Streilein JW
Invest Ophthalmol Vis Sci; 1989 Jun; 30(6):1112-9. PubMed ID: 2732026
[TBL] [Abstract][Full Text] [Related]
23. Critical contribution of CD80 and CD86 to induction of anterior chamber-associated immune deviation.
Tsukahara R; Takeuchi M; Akiba H; Kezuka T; Takeda K; Usui Y; Usui M; Yagita H; Okumura K
Int Immunol; 2005 May; 17(5):523-30. PubMed ID: 15778288
[TBL] [Abstract][Full Text] [Related]
24. The immune response and the eye: the ACAID inducing signal is dependent on the nature of the antigen.
Ferguson TA; Herndon JM
Invest Ophthalmol Vis Sci; 1994 Jun; 35(7):3085-93. PubMed ID: 8206727
[TBL] [Abstract][Full Text] [Related]
25. Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases.
Niederkorn JY; Streilein JW
J Immunol; 1982 Jun; 128(6):2470-4. PubMed ID: 6804562
[TBL] [Abstract][Full Text] [Related]
26. IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis.
Ohta K; Yamagami S; Taylor AW; Streilein JW
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2591-9. PubMed ID: 10937571
[TBL] [Abstract][Full Text] [Related]
27. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye.
Streilein JW
Eye (Lond); 1995; 9 ( Pt 2)():236-40. PubMed ID: 7556724
[TBL] [Abstract][Full Text] [Related]
28. CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation.
Meng Q; Yang P; Li B; Zhou H; Huang X; Zhu L; Ren Y; Kijlstra A
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4444-52. PubMed ID: 17003438
[TBL] [Abstract][Full Text] [Related]
29. Implication for the CD94/NKG2A-Qa-1 system in the generation and function of ocular-induced splenic CD8+ regulatory T cells.
Chattopadhyay S; O'Rourke J; Cone RE
Int Immunol; 2008 Apr; 20(4):509-16. PubMed ID: 18359787
[TBL] [Abstract][Full Text] [Related]
30. Correlation of anterior chamber-associated immune deviation with suppression of corneal epithelial rejection in mice.
Yao YF; Inoue Y; Miyazaki D; Hara Y; Shimomura Y; Tano Y; Ohashi Y
Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):292-300. PubMed ID: 9040461
[TBL] [Abstract][Full Text] [Related]
31. Effect of anterior chamber-associated immune deviation (ACAID) on rat islet allograft rejection.
Koevary SB; Beaudry K
Ocul Immunol Inflamm; 2000 Mar; 8(1):39-47. PubMed ID: 10806433
[TBL] [Abstract][Full Text] [Related]
32. The differing patterns of antigen release and local retention following anterior chamber and intravenous inoculation of soluble antigen. Evidence that the eye acts as an antigen depot.
Wilbanks GA; Streilein JW
Reg Immunol; 1989; 2(6):390-8. PubMed ID: 2485688
[TBL] [Abstract][Full Text] [Related]
33. Loss of anterior chamber-associated immune deviation (ACAID) in aged retinal degeneration (rd) mice.
Welge-Lüssen U; Wilsch C; Neuhardt T; Wayne Streilein J; Lütjen-Drecoll E
Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3209-14. PubMed ID: 10586944
[TBL] [Abstract][Full Text] [Related]
34. Role of tumor necrosis factor receptor expression in anterior chamber-associated immune deviation (ACAID) and corneal allograft survival.
Niederkorn JY; Mayhew E; Mellon J; Hegde S
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2674-81. PubMed ID: 15277491
[TBL] [Abstract][Full Text] [Related]
35. [Expression of programmed death 1 and its ligands in iris-ciliary body from mice with anterior chamber-associated immune deviation].
Meng QL; Yang PZ; Li B; Zhou HY; Huang XK; Zhu LX
Zhonghua Yan Ke Za Zhi; 2008 Jun; 44(6):558-62. PubMed ID: 19035251
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-1 abrogates anterior chamber-associated immune deviation.
Benson JL; Niederkorn JY
Invest Ophthalmol Vis Sci; 1990 Oct; 31(10):2123-8. PubMed ID: 1698740
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation.
Yamada J; Zhu SN; Streilein JW; Dana MR
Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4203-8. PubMed ID: 11095616
[TBL] [Abstract][Full Text] [Related]
38. High-dose cyclophosphamide inhibits anterior chamber-associated immune deviation (ACAID) and the production of extracellular antigen-specific T cell proteins induced by trinitrophenylated (TNP) spleen cells.
Wang Y; O'Rourke J; Cone RE
Cell Immunol; 1995 Oct; 165(2):284-8. PubMed ID: 7553893
[TBL] [Abstract][Full Text] [Related]
39. Impaired induction of delayed hypersensitivity following anterior chamber inoculation of alloantigens.
Williamson JS; Streilein JW
Reg Immunol; 1988; 1(1):15-23. PubMed ID: 2978942
[TBL] [Abstract][Full Text] [Related]
40. Imposing deviant immunity on the presensitized state.
Kosiewicz MM; Okamoto S; Miki S; Ksander BR; Shimizu T; Streilein JW
J Immunol; 1994 Oct; 153(7):2962-73. PubMed ID: 8089480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
